Compare Heron Therapeutics Inc (HRTX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Weibo Corp — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Weibo Corp trades at $6.52 (market cap $1.56B). The key difference: Weibo Corp is far larger — about 22.9× Heron Therapeutics Inc's market cap, and Weibo Corp pays a 9.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Weibo Corp for 102 Days on average.
| HRTX | WB | |
|---|---|---|
Market Cap | $68.01M | $1.56B |
Volume | 1,891,941 | 812,503 |
Sector | Health | Media |
52-Week High | $1.49 | $12.37 |
52-Week Low | $0.27 | $6.33 |
Typical Hold Time | 35 Days | 102 Days |
Enterprise Value | $174.75M | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Weibo (WB) trades at $6.55, up 1.08% with bearish technical indicators but attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported Q2 2026 earnings beat with $449M net income in 2025, though recent quarters show mixed results. Cash flow trends show volatility with a $694M net outflow in 2024, while analyst sentiment remains divided with 40.9% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with strong profitability margins but faces significant headwinds from declining user metrics and advertising challenges. The stock's low valuation multiples suggest potential upside if operational stability improves, though competitive pressures and China's regulatory environment remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
